Please assess the completion status of the following clinical trial:

Trial Title: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years of age.~2. Histologically-confirmed diagnosis according to Revised European American Lymphoma/World Health Organization classification, of the following B-cell lymphomas:~   1. FL~  2. Other indolent NHL (eg, MZL/MALT)~  3. DLBCL~  4. MCL~3. Patients' NHL must have progressed after at least 1 prior rituximab containing regimen.~4. One site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm.~   Exception:~   For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.~5. Patients who have previously received an autologous stem cell transplantation must be at least 4 weeks post-transplant before study drug administration and must have exhibited a full haematological recovery.~6. Discontinued previous monoclonal antibody therapy (except rituximab) or radioimmunotherapy administration for at least 60 days before study drug administration.~7. Off rituximab for at least 14 days before the screening visit and be confirmed to have either no response or have disease progression after rituximab treatment.~8. Patients with DLBCL had a positive \[18F\]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson 2007 response criteria).~9. Life expectancy of \> 3 months.~10. Eastern Cooperative Oncology Group (ECOG) performance status of \< 3.~11. Laboratory criteria at screening:~    1. Absolute neutrophil count (ANC) ≥ 1.0 × 10\^9/L~   2. Platelet count ≥ 75 × 10\^9/L without previous transfusion within 10 days of first study drug administration~   3. Haemoglobin ≥ 8.0 g/dL (may have been transfused)~   4. Serum creatinine \< 2.0 x upper limit of normal (ULN)~   5. Total bilirubin ≤ 2.0 × ULN~   6. Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN~12. If a female of childbearing potential, a negative pregnancy test must be confirmed before enrolment and use of double-barrier contraception or oral contraceptive plus barrier contraceptive must be used during the study and for 3 months after the last dose, or confirmation of having undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation.~13. If a male, an effective barrier method of contraception must be used during the study and for 3 months after the last dose if the patient is sexually active with a female of childbearing potential.~14. Able to comply with all study-related procedures, medication use, and evaluations.~15. Able to understand and give written informed consent and comply with the study protocol.~Exclusion Criteria:~1. Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within 14 days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy.~2. Treatment with a systemic investigational agent within 28 days before the screening visit.~3. Previous treatment with an anti-CD19 antibody or fragments.~4. Previous allogenic stem cell transplantation.~5. Known or suspected hypersensitivity to the excipients contained in the study drug formulation.~6. Clinically significant cardiovascular disease or cardiac insufficiency, cardiomyopathy, preexisting clinically significant arrhythmia, acute myocardial infarction within 3 months of enrolment, angina pectoris within 3 months of enrolment.~7. Patients with positive hepatitis serology:~   Hepatitis B (HBV): Patients with positive serology for HBV defined as positivity for hepatitis B surface antigen (HBsAg) or total anti-hepatitis B core antibody (anti-HBc). Patients positive for anti-HBc may be included if HBV DNA is not detectable.~   Hepatitis C (HCV): Patients positive HCV serology (defined as positive for anti-HCV antibody \[anti-HCV\]) unless HCV-ribonucleic acid (RNA) is confirmed negative.~8. History of HIV infection.~9. Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.~10. Current treatment with immunosuppressive agents other than prescribed corticosteroids (not more than 10-mg prednisone equivalent).~11. Major surgery or radiation therapy within 4 weeks before first study drug administration.~12. Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment in the investigator's opinion.~13. History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis.~14. Active treatment/chemotherapy for another primary malignancy within the past 5 years (except for ductal breast cancer in situ, non-melanoma skin cancer, prostate cancer not requiring treatment, and cervical carcinoma in situ).~15. Pregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control.~16. History of noncompliance to medical regimens or patients who are considered potentially unreliable not cooperative.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MOR00208 (formerly Xmab5574) (Type: EXPERIMENTAL): intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete